Hologic to Unveil Products at ECR - Analyst Blog
February 27 2013 - 9:20AM
Zacks
Leading provider of healthcare
products for women Hologic Inc. (HOLX) is
scheduled to exhibit some of its newest offerings at the annual
meeting of the European Society of Radiology, during Mar 7-11, in
Vienna, Austria. This offers an ideal platform for the company to
showcase its most recent products at the largest radiological
meeting in Europe – the European Congress of Radiology (ECR).
Hologic will display its extensive suite of healthcare solutions
for the screening and diagnosis of breast cancer, breast biopsy,
osteoporosis risk assessment, medical MRI coils and extremity
imaging. Management is enthusiastic about its breast tomosynthesis
program including the introduction of a tomosynthesis biopsy option
for the company’s Affirm breast biopsy guidance system. Hologic
will also conduct education sessions and training workshops for
tomosynthesis-guided breast biopsy.
The company received the European CE Mark for its Selenia
Dimensions breast tomosynthesis system in 2008 following the U.S.
Food and Drug Administration approval in 2011. Apart from Selenia
system and the most recent innovation for the 3D technology
platform – a tomosynthesis biopsy option for the 'Affirm breast
biopsy guidance system', Hologic will also present its latest
version of C-View software. These offerings are expected to improve
standards of patient care and workflow efficiencies.
Moreover, Hologic is set to display two new products at ECR, namely
Selenia Dimensions Avia Package and Flouroscan InSight-FD Mini
C-arm. While the Avia Package provides cost effective 2D screening
and diagnostic solutions, the Mini C-arm will meet the needs of
orthopedic and extremity surgeons by improving workspace access and
ease of positioning.
Given that ECR hosts more than 20,000 participants representing the
medical specialty of radiology across Europe and the Mediterranean,
the exhibition presents a unique opportunity to create brand
awareness for Hologic and thereby promote its innovative
products.
The coherent focus on Selenia is encouraging following the ongoing
shift from Hologic’s legacy Selenia product lines. According to the
company, its breast tomosynthesis technology is ‘game-changing’.
Notably, expectations from the technology are sky-high. However,
over the past few quarters, Hologic witnessed several challenges in
the form of economic uncertainties in Europe, slower sales cycles
and increasing pricing pressure.
In the light of these facts, the estimates for the ongoing fiscal
have remained stagnant over the last 90 days. Accordingly, the
stock carries a Zacks Rank #3 (Hold). While we remain on the
sidelines for Hologic, other medical stocks such as
Cyberonics (CYBX), Given Imaging
(GIVN) and Medical Action (MDCI), each carrying a
Zacks Rank #1 (Strong Buy) are expected to do well.
CYBERONICS INC (CYBX): Free Stock Analysis Report
GIVEN IMAGING (GIVN): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
MEDICAL ACTION (MDCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Aug 2023 to Aug 2024